Search

Introduction and purpose. Preserving fertility is crucial for cancer patients, aligning with advancements in oncology. As survival rates improve, addressing treatment-related late effects gains importance. Many young patients, aware of therapy toxicity, consider future conception chances, impacting treatment decisions. With a trend toward delayed childbirth and a growing population facing unplanned family planning disruptions, the demand for fertility preservation is expected to rise. This paper provides a brief review of available methods for preserving fertility in cancer patients. State of knowledge. Freezing semen in liquid nitrogen vapor is a standard method for preserving reproductive potential in male cancer patients. Shielding during total-body radiation limits testicular volume reduction, indicating less damage to the germinal epithelium. Hormone suppression treatments are not protective in male cancer patients. Oocyte and embryo cryopreservation are considered secure methods before anticancer treatments, with oocyte cryopreservation being preferred for post-pubertal women. Ovarian tissue cryopreservation remains an alternative method without preliminary treatment, suitable when time is insufficient for ovarian stimulation. Ovarian transposition beyond the intended radiation area, performed laparoscopically, can retain ovarian function. GnRH agonist administration before and during chemotherapy aims to minimize the likelihood of premature ovarian insufficiency. Summary. Advancements in fertility preservation for cancer patients, ranging from traditional cryopreservation to innovative methods like ovarian tissue preservation, highlight a commitment to empowering individuals facing cancer diagnoses. Ongoing research expands possibilities, ensuring a diverse range of strategies that offer tangible and hopeful prospects at the intersection of cancer and reproductive health.

Introduction and purpose: Inositol exists in the form of nine isomers, two of which are dominant - myo-inositol (MI) and D-chiro-inositol (DCI). It is a naturally occuring sugar involved in many biological pathways. Due to its insulin-sensitizing, anti-inflammatory and antioxidant properties, inositol has been suggested as a novel treatment agent in prevention and treatment of reproductive disorders. The paper presents currently available data regarding the impact of oral supplementation of inositol for fertility of women and men, reproductive outcomes among subfertile women with polycystic ovarian syndrome (PCOS) and its effectiveness on preventing and treating gestational diabetes mellitus (GDM). Material and methods of research: The search was conducted using PubMed and Google Scholarship databases available to November 2023. Results: Although the evidence is still insufficient, it is suggested that inositol may be beneficial for subfertile women, also those undergoing assisted reproductive techniques and in vitro fertilization. Moreover inositol can positively influence sperm quality. Myoinositol supplementation was also effective and safe for pregnant women with GDM and their children. In these women lower HOMA-IR (Homeostatic Model Assessment – Insulin Resistance) and reduction of fetal macrosomia were observed. Myoinositol also seems to be favorable for overweight or obese women in GDM prevention and treatment. Current findings indicate the positive impact for hormonal changes and restoration in menstrual cyclicity in women with PCOS, improving reproductive disorders in these patients. Conclusions: Overall, although findings are encouraging, further trials for this promising intervention are still required to support oral supplementation of inositol.